Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Staniszewska, Anna"'
Autor:
Hodson D; Division of Pharmacy and Optometry, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom (D.H., H.M., L.A., K.O.); DMPK (S.G., J.Y.) and Biosciences (P.F., A.S.), Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; and DMPK, Research and Early Development, Neuroscience R&D, AstraZeneca, Cambridge, United Kingdom (M.D.)., Mistry H; Division of Pharmacy and Optometry, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom (D.H., H.M., L.A., K.O.); DMPK (S.G., J.Y.) and Biosciences (P.F., A.S.), Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; and DMPK, Research and Early Development, Neuroscience R&D, AstraZeneca, Cambridge, United Kingdom (M.D.)., Yates J; Division of Pharmacy and Optometry, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom (D.H., H.M., L.A., K.O.); DMPK (S.G., J.Y.) and Biosciences (P.F., A.S.), Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; and DMPK, Research and Early Development, Neuroscience R&D, AstraZeneca, Cambridge, United Kingdom (M.D.)., Farrington P; Division of Pharmacy and Optometry, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom (D.H., H.M., L.A., K.O.); DMPK (S.G., J.Y.) and Biosciences (P.F., A.S.), Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; and DMPK, Research and Early Development, Neuroscience R&D, AstraZeneca, Cambridge, United Kingdom (M.D.)., Staniszewska A; Division of Pharmacy and Optometry, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom (D.H., H.M., L.A., K.O.); DMPK (S.G., J.Y.) and Biosciences (P.F., A.S.), Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; and DMPK, Research and Early Development, Neuroscience R&D, AstraZeneca, Cambridge, United Kingdom (M.D.)., Guzzetti S; Division of Pharmacy and Optometry, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom (D.H., H.M., L.A., K.O.); DMPK (S.G., J.Y.) and Biosciences (P.F., A.S.), Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; and DMPK, Research and Early Development, Neuroscience R&D, AstraZeneca, Cambridge, United Kingdom (M.D.)., Davies M; Division of Pharmacy and Optometry, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom (D.H., H.M., L.A., K.O.); DMPK (S.G., J.Y.) and Biosciences (P.F., A.S.), Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; and DMPK, Research and Early Development, Neuroscience R&D, AstraZeneca, Cambridge, United Kingdom (M.D.)., Aarons L; Division of Pharmacy and Optometry, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom (D.H., H.M., L.A., K.O.); DMPK (S.G., J.Y.) and Biosciences (P.F., A.S.), Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; and DMPK, Research and Early Development, Neuroscience R&D, AstraZeneca, Cambridge, United Kingdom (M.D.)., Ogungbenro K; Division of Pharmacy and Optometry, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom (D.H., H.M., L.A., K.O.); DMPK (S.G., J.Y.) and Biosciences (P.F., A.S.), Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; and DMPK, Research and Early Development, Neuroscience R&D, AstraZeneca, Cambridge, United Kingdom (M.D.) kayode.ogungbenro@manchester.ac.uk.
Publikováno v:
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2023 Oct; Vol. 387 (1), pp. 44-54. Date of Electronic Publication: 2023 Jun 22.
Autor:
Dunn S; Wellcome Sanger Institute, Cambridge, UK.; Bioscience, Early Oncology, AstraZeneca, Cambridge, UK., Eberlein C; Bioscience, Early Oncology, AstraZeneca, Alderley Park, UK., Yu J; Wellcome Sanger Institute, Cambridge, UK.; Molecular Biology of Metabolism Lab, The Francis Crick Institute, London, UK., Gris-Oliver A; Vall d'Hebron Institute of Oncology, Barcelona, Spain., Ong SH; Wellcome Sanger Institute, Cambridge, UK., Yelland U; Bioscience, Early Oncology, AstraZeneca, Alderley Park, UK., Cureton N; Bioscience, Early Oncology, AstraZeneca, Alderley Park, UK., Staniszewska A; Bioscience, Early Oncology, AstraZeneca, Cambridge, UK., McEwen R; Bioscience, Early Oncology, AstraZeneca, Cambridge, UK., Fox M; Bioscience, Early Oncology, AstraZeneca, Cambridge, UK., Pilling J; Discovery Sciences, AstraZeneca, Cambridge, UK., Hopcroft P; Discovery Sciences, AstraZeneca, Cambridge, UK., Coker EA; Wellcome Sanger Institute, Cambridge, UK., Jaaks P; Wellcome Sanger Institute, Cambridge, UK., Garnett MJ; Wellcome Sanger Institute, Cambridge, UK., Isherwood B; Discovery Sciences, AstraZeneca, Cambridge, UK., Serra V; Vall d'Hebron Institute of Oncology, Barcelona, Spain., Davies BR; Bioscience, Early Oncology, AstraZeneca, Cambridge, UK., Barry ST; Bioscience, Early Oncology, AstraZeneca, Cambridge, UK. Simon.T.Barry@astrazeneca.com., Lynch JT; Bioscience, Early Oncology, AstraZeneca, Cambridge, UK., Yusa K; Wellcome Sanger Institute, Cambridge, UK. k.yusa@infront.kyoto-u.ac.jp.; Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan. k.yusa@infront.kyoto-u.ac.jp.
Publikováno v:
Oncogene [Oncogene] 2022 Nov; Vol. 41 (46), pp. 5046-5060. Date of Electronic Publication: 2022 Oct 14.
Autor:
Illuzzi G; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Staniszewska AD; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Gill SJ; Oncology Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Pike A; DMPK, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., McWilliams L; Discovery Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Critchlow SE; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Cronin A; Oncology Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Fawell S; Oncology R&D, AstraZeneca, Boston, Massachusetts., Hawthorne G; Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Jamal K; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Johannes J; Chemistry, Oncology R&D, AstraZeneca, Boston, Massachusetts., Leonard E; Discovery Bioanalysis Europe, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Macdonald R; Animal Sciences and Technologies, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Maglennon G; Oncology Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Nikkilä J; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., O'Connor MJ; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Smith A; DMPK, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Southgate H; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Wilson J; DMPK, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Yates J; DMPK, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Cosulich S; Projects Group, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Leo E; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Nov 01; Vol. 28 (21), pp. 4724-4736.
Autor:
Furtak-Niczyporuk M; Uniwersytet Medyczny w Lublinie / Medical University of Lublin, Lublin, Poland (Katedra i Zakład Zdrowia Publicznego / Department of Public Health). marzenafurtakniczyporuk@umlub.pl., Jaroszyński J; Uniwersytet Marii Curie-Skłodowskiej w Lublinie / Maria Curie-Sklodowska University of Lublin, Lublin, Poland (Wydział Prawa i Administracji, Katedra Postępowania Administracyjnego / Faculty of Law and Administration, Department of Administrative Procedure). janusz_jaroszynski@tlen.pl., Mela A; Warszawski Uniwersytet Medyczny / Medical University of Warsaw, Warsaw, Poland (Katedra i Zakład Farmakologii Doświadczalnej i Klinicznej / Department of Experimental and Clinical Pharmacology). aneta.mela@gmail.com., Staniszewska A; Warszawski Uniwersytet Medyczny / Medical University of Warsaw, Warsaw, Poland (Katedra i Zakład Farmakologii Doświadczalnej i Klinicznej / Department of Experimental and Clinical Pharmacology). anna.staniszewska@wum.edu.pl., Piotrowska J; Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi / Copernicus Provincial Multidisciplinary Centre of Oncology and Traumatology in Lodz, Łódź, Poland. jowitapio@interia.pl., Zimmermann A; Uniwersytet Medyczny w Gdańsku / Medical University of Gdansk, Gdańsk, Poland (Zakład Prawa Medycznego i Farmaceutycznego / Department of Medical and Pharmacy Law). agnieszka.zimmermann@gumed.edu.pl., Czajka-Bełz A; Centralny Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji w Warszawie / Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Warsaw, Poland (Klinika Neurologii / Clinical Department of Neurology). anna.czajka@cskmswia.pl., Dreher P; Uniwersytet Medyczny w Lublinie / Medical University of Lublin, Lublin, Poland (Katedra i Zakład Zdrowia Publicznego / Department of Public Health). piotr.dreher@lublin.eu., Dąbrowski J; Instytut Medycyny Doświadczalnej i Klinicznej. im. M. Mossakowskiego Polskiej Akademii Nauk / Mossakowski Medical Research Centre Polish Academy of Sciences, Warsaw, Poland (Zakład Fizjologii Stosowanej / Department of Applied Physiology). jandab@imdik.pan.pl., Kapka-Skrzypczak L; Instytut Medycyny Wsi im. Witolda Chodźki w Lublinie / Witold Chodźko Institute of Rural Health in Lublin, Lublin, Poland (Zakład Biologii Medycznej i Badań Translacyjnych / Department of Molecular Biology and Translational Research).
Publikováno v:
Medycyna pracy [Med Pr] 2019 Jun 14; Vol. 70 (3), pp. 377-391. Date of Electronic Publication: 2019 May 14.
Autor:
Carnevalli LS; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK. Larissa.Carnevalli@astrazeneca.com., Sinclair C; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK., Taylor MA; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK., Gutierrez PM; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK., Langdon S; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK.; Present Address: University of Birmingham, B15 2TT, Birmingham, UK., Coenen-Stass AML; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK., Mooney L; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Alderley Park, Alderley Edge, Macclesfield, SK10 4TG, UK.; Present Address: Alderley Park Limited, Preclinical Services, Alderley Park, Macclesfield, SK10 4TG, UK., Hughes A; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK., Jarvis L; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK., Staniszewska A; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK., Crafter C; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK., Sidders B; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK., Hardaker E; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK., Hudson K; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Alderley Park, Alderley Edge, Macclesfield, SK10 4TG, UK.; Present Address: 2theNth, Adelphi Group, Bollington, SK10 5JB, UK., Barry ST; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK. Simon.T.Barry@astrazeneca.com.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2018 Dec 27; Vol. 6 (1), pp. 158. Date of Electronic Publication: 2018 Dec 27.